                         SEQUENCE LISTING

<110>  ACUMEN RESEARCH LABORATORIES PTE. LTD.
       ONG, Siew-Hwa
 
<120>  METHODS AND KITS FOR IMPROVED PCR

<130>  YF/as/2020.P01963

<150>  SG 10202003067V
<151>  2020-04-01

<160>  12    

<170>  PatentIn version 3.5

<210>  1
<211>  204
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  target in RdRp of severe acute respiratory syndrome coronavirus 2
       (SARS-CoV-2)

<400>  1
cttgtcacac cgtttctata gattagctaa tgagtgtgct caagtattga gtgaaatggt       60

catgtgtggc ggttcactat atgttaaacc aggtggaacc tcatcaggag atgccacaac      120

tgcttatgct aatagtgttt ttaacatttg tcaagctgtc acggccaatg ttaatgcact      180

tttatctact gatggtaaca aaat                                             204


<210>  2
<211>  206
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
       target expressing envelope protein

<400>  2
atgagtacga acttatgtac tcattcgttt cggaagagac aggtacgtta atagttaata       60

gcgtacttct ttttcttgct ttcgtggtat tcttgctagt tacactagcc atccttactg      120

cgcttcgatt gtgtgcgtac tgctgcaata ttgttaacgt gagtcttgta aaaccttctt      180

tttacgttta ctctcgtgtt aaaaat                                           206


<210>  3
<211>  22
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  SARS CoV2 RdRp forward primer

<400>  3
gtgaratggt catgtgtggc gg                                                22


<210>  4
<211>  26
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  SARS CoV 2 RdRp reverse primer

<400>  4
caratgttaa asacactatt agcata                                            26


<210>  5
<211>  25
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  SARS CoV2 RdRp probe

<400>  5
caggtggaac ctcatcagga gatgc                                             25


<210>  6
<211>  26
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  SARS CoV2 envelope forward primer

<400>  6
acaggtacgt taatagttaa tagcgt                                            26


<210>  7
<211>  22
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  SARS CoV2 envelope reverese primer

<400>  7
atattgcagc agtacgcaca ca                                                22


<210>  8
<211>  26
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  SARS CoV2 envelope probe

<400>  8
acactagcca tccttactgc gcttcg                                            26


<210>  9
<211>  248
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  target from MS2 phage

<400>  9
cggtcgtttt aactcgactg gggccaaaac gaaacagtgg cactacccct ctccgtattc       60

acggggggcg ttaagtgtca catcgataga tcaaggtgcc tacaagcgaa gtgggtcatc      120

gtggggtcgc ccgtacgagg agaaagccgg tttcggcttc tccctcgacg cacgctcctg      180

ctacagcctc ttccctgtaa gccaaaactt gacttacatc gaagtgccgc agaacgttgc      240

gaaccggg                                                               248


<210>  10
<211>  25
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  control forward primer

<400>  10
tggcactacc cctctccgta ttcac                                             25


<210>  11
<211>  22
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  control reverse primer

<400>  11
gtacgggcga ccccacgatg ac                                                22


<210>  12
<211>  29
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  control probe

<400>  12
cacatcgata gatcaaggtg cctacaagc                                         29


